EMA Proposes Significant Changes To Guidance On Risk Management Plans And Template
This article was originally published in SRA
The European Medicines Agency has proposed significant changes to its pharmacovigilance guideline on risk management plans to further clarify how drug companies should address identified or potential risks of a drug and tackle "missing information" about a product in an RMP. Also, major changes have been proposed to the integrated RMP template1,2.
Register for our free email digests: